Remifentanil for Procedural Sedation and Analgesia in Central Venous Catheter Insertion
| Autor: | Guillaume Ducos, Jean-Marie Conil, Caroline Samier, Agnès Sommet, Stein Silva, Jean Ruiz, Vincent Minville, Fanny Vardon Bounes, Olivier Fourcade, Xavier Pichon |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Lidocaine medicine.medical_treatment Remifentanil Pain Procedural Placebo law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial 030202 anesthesiology law medicine Central Venous Catheters Humans Hypnotics and Sedatives Anesthetics Local Aged business.industry Middle Aged medicine.disease Analgesics Opioid Anesthesiology and Pain Medicine Anesthesia Procedural sedation and analgesia Anxiety Female Neurology (clinical) medicine.symptom business Infiltration (medical) 030217 neurology & neurosurgery Central venous catheter medicine.drug |
| Zdroj: | The Clinical Journal of Pain. 35:691-695 |
| ISSN: | 0749-8047 |
| DOI: | 10.1097/ajp.0000000000000725 |
| Popis: | Central venous catheter (CVC) insertion is a common practice for anesthetists, but this invasive procedure generates anxiety and pain in patients that are often underestimated. We compared target-controlled infusion of remifentanil and local lidocaine infiltration with placebo and local lidocaine infiltration to decrease pain scores during CVC placement.We included conscious, adult patients without contraindication to remifentanil or lidocaine. We excluded pregnant women, emergency situations, and opioid abuse. Patients requiring CVC were randomly assigned, using computer-generated allocation numbers stored in sealed envelopes, to receive target-controlled infusion of remifentanil or placebo-all patients received local anesthesia with lidocaine. All patients were hospitalized in a recovery room or intensive care unit, monitored, and received 4 L/min of oxygen.The primary outcome was global pain (Verbal Numeric Rating Pain Scale) during the procedure. Secondary outcomes were pain perceived at every stage of the procedure, anxiety, patient satisfaction, operational ease, and side effects.In this double-blind study, we included 90 patients (split into 2 groups of 45 patients). Global pain was significantly reduced in the remifentanil group: 20 of 100 (95% confidence interval, 16-40) versus 50 of 100 (95% confidence interval, 40-60) in the placebo group; P=0.0009. No major adverse events were observed during this study, and there were no significant differences between both groups regarding side effects.Target-controlled infusion of remifentanil is an effective drug to reduce pain during CVC insertion in association with lidocaine-based local anesthesia, in conscious patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|